Hoechst pi

Cell culture media and additives were obtained from the HyClone Company (Beijing, China). N-acetyl-L-cysteine (>99%), Salubrinal, Hoechst/PI and a Reactive Oxygen Species Assay Kit were purchased from Beyotime Biotechnology (Shanghai, China). The 3-methyladenine was purchased from Sigma-Aldrich (Shanghai, China). Hydroxychloroquine was purchased from Tokyo Chemical Industry (Shanghai, China). GSK2606414 (>99.38) was purchased from Med Chen Express (New Zealand, USA). PERK (Cat. No. 3192), IRE1a (Cat. No. 3294) and p62(Cat. No. 5114) antibodies were purchased from Cell Signaling Technology (Shanghai, China). EIF2a (Cat. No.sc-133132) antibodies were acquired from Santa Cruz Biotechnology (Beijing, China). Rhodopsin (Cat. No. OM186133) antibodies were purchased from OmnimAbs (Shanghai, China). LC3B (Cat. No. ab192890) antibodies were purchased from Abcam (Cambridge, MA, USA). BECN1 (Cat. No. 11306-1-AP) antibodies were purchased from Proteintech (Wuhan, China). P-IRE1a (Cat. No. 13013), p-PERK (Cat. No. 12814), ATF6 (Cat. No. 24382), p-EIF2a (Cat. No. 11279), ATF4 (Cat. No. 32007), CHOP (Cat. No. 40744), RPE65(Cat. No. 49495), β-actin (Cat. No. 21800) and secondary antibodies were obtained from Signalway Technology (St. Louis, MO, USA).

Cell culture media and additives were obtained from the HyClone Company (Beijing, China). Antibodies for mTOR (Cat. No. 32028), p-mTOR (Cat. No. 109268), p-S6K1 (Cat. No. 131436), and p-4EBP1 (Cat. No. 75767) were purchased from Abcam (Cambridge, MA, USA). PARP-1 (Cat. No. 9542S) and SIRT1 (Cat. No. 9475 T) antibodies were purchased from Cell Signaling Technology (Shanghai, China). pADPr (PAR) (Cat. No. 56198) and AIF (Cat. No. 9416) antibodies were acquired from Santa Cruz Biotechnology (Beijing, China). The β-ACTIN (Cat. No. 21800) and LaminB1 (Cat. No. 40413) antibodies, in addition to secondary antibodies, were obtained from Signalway Technology (St. Louis, MO, USA). Hoechst/PI and EX527 (a SIRT1 inhibitor) were purchased from Beyotime Biotechnology (Shanghai, China). Rapamycin (an mTOR inhibitor) and 3-Aminobenzamide (3AB, a PARP-1 inhibitor) were obtained from Abmole (Beijing, China). All other reagents were acquired from Sigma-Aldrich (Shanghai, China).